Eslicarbazepine acetate vs Rufinamide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Eslicarbazepine acetate · Aptiom

Marketed by Sumitomo Pharma and partners

Approved in Epilepsysmall molecule
Partial signal

NCT00957684 · Phase 3 · completed

Study BIA-2093-301 was a randomized, double-blind, placebo-controlled Phase 3 trial in 402 adults with refractory partial-onset seizures, testing once-daily eslicarbazepine acetate 400, 800 and 1200 mg against placebo. The single primary endpoint was seizure frequency over the maintenance period. The 800 mg and 1200 mg doses met it (p=0.0028 and p=0.0003); the 400 mg dose did not. Because one tested dose missed, the call is mixed, as in the wave 121 Stempeucel dose-arm precedent. Source: the peer-reviewed paper (Elger et al., Epilepsia 2009).

Reported efficacy

Time to treatment failure (up to 2 years): Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group

Result source: NCT02484001

Rufinamide

Marketed by Eisai and partners

Approved in Epilepsysmall molecule
Partial signal

NCT00334958 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 study gave adjunctive rufinamide 3,200 mg/day or placebo to adolescents and adults with refractory partial-onset seizures (357 randomized). Its single registered primary endpoint was the percentage change in total partial seizure frequency per 28 days. The median reduction was 23.25% with rufinamide and 9.80% with placebo, and the peer-reviewed paper reports p = 0.007, so the primary endpoint was met. The registry posts the same medians but no statistical test; the p-value comes from Biton et al., Epilepsia 2011.

The p-value comes from the peer-reviewed paper (Biton et al., Epilepsia 2011); ClinicalTrials.gov posts the medians with no statistical analysis.

Reported efficacy

Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase (Baseline, Days 13 to 96): Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). (met)

Result source: NCT00334958

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEslicarbazepine acetateRufinamide
Seizure frequency, % change—Not posted · NCT02484001—Not reported
50% responder rate30.6% vs 31%−0.4 vs placebon 134NCT00988156
2 other results
  • 54% vs 28% once daily · wk 12 · n 50 · Phase 2 · primary NCT02170077
  • 41% vs 28% twice daily · wk 12 · n 46 · Phase 2 · primary NCT02170077
—Not reported
Seizure freedom—Not posted · NCT02484001—Not reported

Seizure frequency, % change

Eslicarbazepine acetate
—Not posted · NCT02484001
Rufinamide
—Not reported

50% responder rate

Eslicarbazepine acetate
30.6% vs 31%−0.4 vs placebon 134NCT00988156
2 other results
  • 54% vs 28% once daily · wk 12 · n 50 · Phase 2 · primary NCT02170077
  • 41% vs 28% twice daily · wk 12 · n 46 · Phase 2 · primary NCT02170077
Rufinamide
—Not reported

Seizure freedom

Eslicarbazepine acetate
—Not posted · NCT02484001
Rufinamide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Eslicarbazepine acetate: 4 of 4 rows · Rufinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEslicarbazepine acetateRufinamide
Dropout rate
13.3%800 mg once dailya
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
show 50 more results
30.4%1200 mg once daily
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
10%400 mg once daily
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
—800 mg
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
20.8%800 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—1200 mg
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
30.6%1200 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—400 mg
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
13.5%400 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—ESL PART II
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
12.9%
NCT00988156 · Phase 3 · monotherapy · Epilepsy · phase 3
—
NCT02912364 · Phase 4 · registry result, not featured evidence
25.2%
NCT00910247 · Phase 3 · registry result, not featured evidence
30.6%800 mg
NCT01422720 · Phase 3 · registry result, not featured evidence
40.6%1600 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
55.4%1200 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
—1600 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
29.3%1200 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
—1200 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
—800 mg QD
NCT00988429 · Phase 3 · registry result, not featured evidence
—1200 mg QD
NCT00988429 · Phase 3 · registry result, not featured evidence
—800 mg
NCT00957372 · Phase 3 · registry result, not featured evidence
—1200 mg
NCT00957372 · Phase 3 · registry result, not featured evidence
9.6%Esl (BIA 2-093)
NCT01527513 · Phase 2 · registry result, not featured evidence
—Part I - ESL
NCT01527513 · Phase 2 · registry result, not featured evidence
—Part II - ESL
NCT01527513 · Phase 2 · registry result, not featured evidence
0%
NCT02021461 · Phase 2 · registry result, not featured evidence
—once daily
NCT02170077 · Phase 2 · registry result, not featured evidence
—twice daily
NCT02170077 · Phase 2 · registry result, not featured evidence
—Eslicarbazepine Acetate
NCT00987558 · Phase 1 · registry result, not featured evidence
—Eslicarbazepine Acetate + Simvasta
NCT00987558 · Phase 1 · registry result, not featured evidence · combination
0%
NCT00900237 · Phase 1 · registry result, not featured evidence
5%
NCT00898560 · Phase 1 · registry result, not featured evidence · combination
—800 mg
NCT02284828 · Phase 1 · registry result, not featured evidence
—1200 mg
NCT02284828 · Phase 1 · registry result, not featured evidence
—900 mg
NCT02284828 · Phase 1 · registry result, not featured evidence
—800 mg (2 x 400 mg)
NCT02288312 · Phase 1 · registry result, not featured evidence
—800 mg fasting
NCT02288312 · Phase 1 · registry result, not featured evidence
—800 mg fed
NCT02288312 · Phase 1 · registry result, not featured evidence
0%800 mg
NCT02283840 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT02283840 · Phase 1 · registry result, not featured evidence
5%600 mg
NCT02283840 · Phase 1 · registry result, not featured evidence
—Test 1
NCT02283840 · Phase 1 · registry result, not featured evidence
—Test 2
NCT02283840 · Phase 1 · registry result, not featured evidence
—Test 3
NCT02283840 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone3600 mg Once Daily
NCT01879332 · Phase 1 · registry result, not featured evidence
n/a: no completion milestone3000 mg Once Daily
NCT01879332 · Phase 1 · registry result, not featured evidence
18.8%Group A BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
12.5%Group B BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
0%
NCT02281591 · Phase 1 · registry result, not featured evidence
—1200 mg once-daily
NCT02281448 · Phase 1 · registry result, not featured evidence · combination
21%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
13.8%
NCT01146951 · Phase 3 · monotherapy
40%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
24.1%
NCT01151540 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—800 mg once dailya
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
show 50 more results
—1200 mg once daily
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
—400 mg once daily
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
—800 mg
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—800 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—1200 mg
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—1200 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—400 mg
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—400 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—ESL PART II
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—
NCT00988156 · Phase 3 · monotherapy · Epilepsy · phase 3
—
NCT02912364 · Phase 4 · registry result, not featured evidence
5.5%
NCT00910247 · Phase 3 · registry result, not featured evidence
22.2%800 mg
NCT01422720 · Phase 3 · registry result, not featured evidence
14.8%1600 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
7.7%1200 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
—1600 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
1.7%1200 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
—1200 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
—800 mg QD
NCT00988429 · Phase 3 · registry result, not featured evidence
—1200 mg QD
NCT00988429 · Phase 3 · registry result, not featured evidence
—800 mg
NCT00957372 · Phase 3 · registry result, not featured evidence
—1200 mg
NCT00957372 · Phase 3 · registry result, not featured evidence
—Esl (BIA 2-093)
NCT01527513 · Phase 2 · registry result, not featured evidence
—Part I - ESL
NCT01527513 · Phase 2 · registry result, not featured evidence
—Part II - ESL
NCT01527513 · Phase 2 · registry result, not featured evidence
—
NCT02021461 · Phase 2 · registry result, not featured evidence
—once daily
NCT02170077 · Phase 2 · registry result, not featured evidence
—twice daily
NCT02170077 · Phase 2 · registry result, not featured evidence
—Eslicarbazepine Acetate
NCT00987558 · Phase 1 · registry result, not featured evidence
—Eslicarbazepine Acetate + Simvasta
NCT00987558 · Phase 1 · registry result, not featured evidence · combination
—
NCT00900237 · Phase 1 · registry result, not featured evidence
—
NCT00898560 · Phase 1 · registry result, not featured evidence · combination
—800 mg
NCT02284828 · Phase 1 · registry result, not featured evidence
—1200 mg
NCT02284828 · Phase 1 · registry result, not featured evidence
—900 mg
NCT02284828 · Phase 1 · registry result, not featured evidence
—800 mg (2 x 400 mg)
NCT02288312 · Phase 1 · registry result, not featured evidence
—800 mg fasting
NCT02288312 · Phase 1 · registry result, not featured evidence
—800 mg fed
NCT02288312 · Phase 1 · registry result, not featured evidence
—800 mg
NCT02283840 · Phase 1 · registry result, not featured evidence
—400 mg
NCT02283840 · Phase 1 · registry result, not featured evidence
—600 mg
NCT02283840 · Phase 1 · registry result, not featured evidence
—Test 1
NCT02283840 · Phase 1 · registry result, not featured evidence
—Test 2
NCT02283840 · Phase 1 · registry result, not featured evidence
—Test 3
NCT02283840 · Phase 1 · registry result, not featured evidence
—3600 mg Once Daily
NCT01879332 · Phase 1 · registry result, not featured evidence
—3000 mg Once Daily
NCT01879332 · Phase 1 · registry result, not featured evidence
—Group A BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
—Group B BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
—
NCT02281591 · Phase 1 · registry result, not featured evidence
—1200 mg once-daily
NCT02281448 · Phase 1 · registry result, not featured evidence · combination
15.3%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
13.8%
NCT01146951 · Phase 3 · monotherapy
12%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
7.4%
NCT01151540 · Phase 3 · registry result, not featured evidence
Serious AEs
4.1%800 mg once dailya
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
show 50 more results
2.9%1200 mg once daily
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
9%400 mg once daily
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
5.9%800 mg
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—800 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
2%1200 mg
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—1200 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
4.2%400 mg
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—400 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
8.6%ESL PART II
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
—
NCT00988156 · Phase 3 · monotherapy · Epilepsy · phase 3
0%
NCT02912364 · Phase 4 · registry result, not featured evidence
11.7%
NCT00910247 · Phase 3 · registry result, not featured evidence
15.3%800 mg
NCT01422720 · Phase 3 · registry result, not featured evidence
6.3%1600 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
6.2%1200 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
7%1600 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
—1200 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
1.7%1200 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
6.5%800 mg QD
NCT00988429 · Phase 3 · registry result, not featured evidence
1.4%1200 mg QD
NCT00988429 · Phase 3 · registry result, not featured evidence
0%800 mg
NCT00957372 · Phase 3 · registry result, not featured evidence
1.3%1200 mg
NCT00957372 · Phase 3 · registry result, not featured evidence
—Esl (BIA 2-093)
NCT01527513 · Phase 2 · registry result, not featured evidence
3.6%Part I - ESL
NCT01527513 · Phase 2 · registry result, not featured evidence
7.1%Part II - ESL
NCT01527513 · Phase 2 · registry result, not featured evidence
2.6%
NCT02021461 · Phase 2 · registry result, not featured evidence
4%once daily
NCT02170077 · Phase 2 · registry result, not featured evidence
0%twice daily
NCT02170077 · Phase 2 · registry result, not featured evidence
0%Eslicarbazepine Acetate
NCT00987558 · Phase 1 · registry result, not featured evidence
0%Eslicarbazepine Acetate + Simvasta
NCT00987558 · Phase 1 · registry result, not featured evidence · combination
0%
NCT00900237 · Phase 1 · registry result, not featured evidence
0%
NCT00898560 · Phase 1 · registry result, not featured evidence · combination
0%800 mg
NCT02284828 · Phase 1 · registry result, not featured evidence
0%1200 mg
NCT02284828 · Phase 1 · registry result, not featured evidence
0%900 mg
NCT02284828 · Phase 1 · registry result, not featured evidence
0%800 mg (2 x 400 mg)
NCT02288312 · Phase 1 · registry result, not featured evidence
0%800 mg fasting
NCT02288312 · Phase 1 · registry result, not featured evidence
0%800 mg fed
NCT02288312 · Phase 1 · registry result, not featured evidence
—800 mg
NCT02283840 · Phase 1 · registry result, not featured evidence
—400 mg
NCT02283840 · Phase 1 · registry result, not featured evidence
—600 mg
NCT02283840 · Phase 1 · registry result, not featured evidence
0%Test 1
NCT02283840 · Phase 1 · registry result, not featured evidence
0%Test 2
NCT02283840 · Phase 1 · registry result, not featured evidence
0%Test 3
NCT02283840 · Phase 1 · registry result, not featured evidence
0%3600 mg Once Daily
NCT01879332 · Phase 1 · registry result, not featured evidence
0%3000 mg Once Daily
NCT01879332 · Phase 1 · registry result, not featured evidence
0%Group A BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
0%Group B BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
0%
NCT02281591 · Phase 1 · registry result, not featured evidence
5%1200 mg once-daily
NCT02281448 · Phase 1 · registry result, not featured evidence · combination
3.4%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
3.4%
NCT01146951 · Phase 3 · monotherapy
40%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
16.7%
NCT01151540 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
800 mg once dailya
dizziness 14.3% (placebo 2%)
headache 9.2% (placebo 5.9%)
somnolence 9.2% (placebo 2%)
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
show 40 more results
1200 mg once daily
dizziness 13.7% (placebo 2%)
diplopia 10.8% (placebo 0%)
headache 10.8% (placebo 5.9%)
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
400 mg once daily
somnolence 6% (placebo 2%)
headache 5% (placebo 5.9%)
dizziness 4% (placebo 2%)
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
800 mg
dizziness 29.7% (placebo 10%)
somnolence 16.8% (placebo 17%)
diplopia 14.9% (placebo 4%)
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
1200 mg
dizziness 43.9% (placebo 10%)
somnolence 21.4% (placebo 17%)
headache 19.4% (placebo 9%)
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
400 mg
dizziness 22.9% (placebo 10%)
somnolence 15.6% (placebo 17%)
headache 12.5% (placebo 9%)
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
dizziness 26.5% (placebo 10%)
headache 15.7% (placebo 9%)
somnolence 12% (placebo 17%)
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
fatigue 34.5%
headache 10.3%
clouded vision 3.4%
NCT02912364 · Phase 4 · registry result, not featured evidence
headache 23.4%
dizziness 16.8%
nasopharyngitis 8.8%
NCT00910247 · Phase 3 · registry result, not featured evidence
800 mg
dizziness 12.5%
somnolence 9.7%
convulsion 8.3%
NCT01422720 · Phase 3 · registry result, not featured evidence
1600 mg QD
dizziness 24.2%
headache 20.3%
somnolence 18%
NCT00866775 · Phase 3 · registry result, not featured evidence
1200 mg QD
dizziness 27.7%
headache 21.5%
fatigue 20%
NCT00866775 · Phase 3 · registry result, not featured evidence
1600 mg
headache 28.1%
dizziness 21.1%
solmnolence 8.8%
NCT01091662 · Phase 3 · registry result, not featured evidence
1200 mg
headache 19%
dizziness 10.3%
nausea 10.3%
NCT01091662 · Phase 3 · registry result, not featured evidence
800 mg QD
dizziness 15.7% (placebo 8.5%)
headache 9.3% (placebo 7.6%)
nausea 7.4% (placebo 4.9%)
NCT00988429 · Phase 3 · registry result, not featured evidence
1200 mg QD
dizziness 26.2% (placebo 8.5%)
somnolence 17.1% (placebo 5.4%)
nausea 15.2% (placebo 4.9%)
NCT00988429 · Phase 3 · registry result, not featured evidence
800 mg
dizziness 18.8% (placebo 10.3%)
somnolence 12.9% (placebo 9.2%)
headache 5.9% (placebo 11.5%)
NCT00957372 · Phase 3 · registry result, not featured evidence
1200 mg
dizziness 30% (placebo 10.3%)
somnolence 13.8% (placebo 9.2%)
headache 10% (placebo 11.5%)
NCT00957372 · Phase 3 · registry result, not featured evidence
headache 9.6% (placebo 15%)
somnolence 6% (placebo 5%)
vomiting 6% (placebo 2.5%)
NCT01527513 · Phase 2 · registry result, not featured evidence
headache 5.4% (placebo 15%)
respiratory tract infection viral 5.4% (placebo 0%)
convulsion 3.6% (placebo 0%)
NCT01527513 · Phase 2 · registry result, not featured evidence
once daily
somnolence 6% (placebo 0%)
hair loss 4% (placebo 2.1%)
headache 4% (placebo 6.4%)
NCT02170077 · Phase 2 · registry result, not featured evidence
twice daily
headache 17.4% (placebo 6.4%)
dizziness 10.9% (placebo 2.1%)
vomiting 10.9% (placebo 2.1%)
NCT02170077 · Phase 2 · registry result, not featured evidence
fatigue 40%
headache 20%
rash morbilliform 10%
NCT00987558 · Phase 1 · registry result, not featured evidence
orthostatic hypotension 10%
headache 6.7%
pharyngitis 3.3%
NCT00987558 · Phase 1 · registry result, not featured evidence · combination
dizziness 42.9%
fatigue 28.6%
headache 28.6%
NCT00900237 · Phase 1 · registry result, not featured evidence
somnolence 40%
headache 30%
dizziness 25%
NCT00898560 · Phase 1 · registry result, not featured evidence · combination
800 mg
nausea 11.5% (placebo 19.2%)
dizziness 7.7% (placebo 3.8%)
headache 7.7% (placebo 3.8%)
NCT02284828 · Phase 1 · registry result, not featured evidence
1200 mg
headache 7.7% (placebo 3.8%)
hypoaesthesia 7.7% (placebo 0%)
paraesthesia 7.7% (placebo 3.8%)
NCT02284828 · Phase 1 · registry result, not featured evidence
900 mg
nausea 7.7% (placebo 19.2%)
somnolence 7.7% (placebo 11.5%)
abdominal distension 3.8% (placebo 3.8%)
NCT02284828 · Phase 1 · registry result, not featured evidence
800 mg (2 x 400 mg)
cpk increased 5.9%
somnolence 5.9%
diarrhoea 0%
NCT02288312 · Phase 1 · registry result, not featured evidence
800 mg fasting
diarrhoea 5.6%
tonsillitis 5.6%
tooth extraction 5.6%
NCT02288312 · Phase 1 · registry result, not featured evidence
800 mg fed
cpk increased 5.9%
pregnancy 5.9%
somnolence 5.9%
NCT02288312 · Phase 1 · registry result, not featured evidence
somnolence 20%
back pain 5%
eye pruritus 5%
NCT02283840 · Phase 1 · registry result, not featured evidence
somnolence 31.6%
dizziness 5.3%
electrocardigram qt corrected interval prolonged 5.3%
NCT02283840 · Phase 1 · registry result, not featured evidence
somnolence 20%
constipation 5%
disturbance in attention 5%
NCT02283840 · Phase 1 · registry result, not featured evidence
3600 mg Once Daily
dizziness 83.3% (placebo 25%)
somnolence 66.7% (placebo 25%)
vomiting 50% (placebo 0%)
NCT01879332 · Phase 1 · registry result, not featured evidence
3000 mg Once Daily
dizziness 83.3% (placebo 25%)
fatigue 66.7% (placebo 0%)
vomiting 66.7% (placebo 0%)
NCT01879332 · Phase 1 · registry result, not featured evidence
somnolence 87.5%
paraesthesia oral 50%
headache 43.8%
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
somnolence 81.3%
abdominal distension 43.8%
fatigue 37.5%
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
headache 37.5%
dizziness 25%
accidental injury 12.5%
NCT02281591 · Phase 1 · registry result, not featured evidence
1200 mg once-daily
somnolence 73.7%
dizziness 52.6%
constipation 26.3%
NCT02281448 · Phase 1 · registry result, not featured evidence · combination
b
dizziness 26.7% (placebo 8.3%)
headache 16.5% (placebo 12.8%)
fatigue 15.3% (placebo 10%)
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
nasopharyngitis 31% (placebo 30%)
status epilepticus 27.6% (placebo 16.7%)
decreased appetite 20.7% (placebo 6.7%)
NCT01146951 · Phase 3 · monotherapy
upper respiratory tract infection 28%
vomiting 28%
somnolence 20%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
nasopharyngitis 48.1%
status epilepticus 40.7%
somnolence 25.9%
NCT01151540 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 40 of these studies.
  2. bPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Eslicarbazepine acetate

Seizure Frequency 5.66 vs 7.64 placebo per 4 week @ 12wk800 mg
absolute change · per 4 week
Maintenance
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
show 2 more results
5.35 vs 7.64 placebo per 4 week @ 12wk1200 mg
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
6.73 vs 7.64 placebo per 4 week @ 12wk400 mg
NCT00957684 · Phase 3 · monotherapy · Epilepsy · phase 3
Seizure Frequency 7.1 vs 9.8 placebo per 4 week800 mg once daily
absolute value · per 4 week
Maintenance
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
show 2 more results
7 vs 9.8 placebo per 4 week1200 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
8.7 vs 9.8 placebo per 4 week400 mg once daily
NCT00957047 · Phase 3 · monotherapy · Epilepsy · phase 3
Seizure Frequency Change Per 36.6 vs 62 placebo per month
absolute change · per month
NCT00988156 · Phase 3 · monotherapy · Epilepsy · phase 3
Seizure 50 30.6% (n=134) vs 31% (n=129) placebo
responder rate · % of participants
NCT00988156 · Phase 3 · monotherapy · Epilepsy · phase 3 · converted to % from 41 participants as posted
show 2 more results
54% (n=50) vs 28% (n=47) placebo @ 12wkonce daily
NCT02170077 · Phase 2 · registry result, not featured evidence
41% (n=46) vs 28% (n=47) placebo @ 12wktwice daily
NCT02170077 · Phase 2 · registry result, not featured evidence
Cognitive Composite Z Score 0.001 vs -0.23 Carbamazepine Z-score @ 6wk
absolute change · Z-score
NCT02912364 · Phase 4 · registry result, not featured evidence
Executive Composite Z-score 0.22 vs -0.32 Carbamazepine Z-score @ 6wk
absolute change · Z-score
NCT02912364 · Phase 4 · registry result, not featured evidence
Seizure Frequency -66.4% (n=274) @ 52wk
percent change · % of baseline
No placebo or comparator arm
NCT00910247 · Phase 3 · registry result, not featured evidence
Seizure 50 62.4% (n=274) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT00910247 · Phase 3 · registry result, not featured evidence
Seizure-free 7.6% (n=118)1600 mg QD
responder rate · % of participants
No placebo or comparator arm
NCT00866775 · Phase 3 · registry result, not featured evidence
show 8 more results
14.4% (n=118)1600 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
10% (n=100) @ 18wk1600 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
17% (n=100) @ 18wk1600 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
8.3% (n=60)1200 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
13.3% (n=60)1200 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
7.4% (n=54) @ 18wk1200 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
16.7% (n=54) @ 18wk1200 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
7.3% (n=274) @ 52wk
NCT00910247 · Phase 3 · registry result, not featured evidence
QOLIE-31-P 6.6 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00910247 · Phase 3 · registry result, not featured evidence
MADRS -1.5 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00910247 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.5 score @ 52wk
NCT00910247 · Phase 3 · registry result, not featured evidence
Treatment Failure 0.287% (n=118)1600 mg QD
event count · % of participants
No placebo or comparator arm
NCT00866775 · Phase 3 · registry result, not featured evidence
show 3 more results
0.128% (n=100) @ 18wk1600 mg
NCT01091662 · Phase 3 · registry result, not featured evidence
0.444% (n=60)1200 mg QD
NCT00866775 · Phase 3 · registry result, not featured evidence
0.156% (n=54) @ 18wk1200 mg
NCT01091662 · Phase 3 · registry result, not featured evidence

+ 30 further endpoints in the CSV export.

Rufinamide

Seizure Frequency 50 32.5% (n=160) vs 14.3% (n=175) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
Tonic-atonic Seizure 50% Reduction 25% (n=28) vs 6.7% (n=30) placebo @ 12wk
event count · % of participants
Yes (50% Reduction Achieved)
NCT01146951 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
Drop Seizure Frequency -39.3% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -40.6% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -46.8% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -47.6% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -36.05% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.7% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -48.9% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -50.6% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -52% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.35% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eslicarbazepine acetate's landscape · Rufinamide's landscape